ArticleJournal for immunotherapy of cancer2021

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.

Kevin Dang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.